Quince Therapeutics, Inc.
News
Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Business Wire Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases, today announced that Dirk...\n more…
Quince Therapeutics, Inc. (NASDAQ:QNCX) President Charles S. Ryan Purchases 48,387 Shares
Ticker Report Quince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) President Charles S. Ryan bought 48,387 shares of the stock in a transaction that occurred on Tuesday, August 20th. The stock was bought at...\n more…
Quince Therapeutics, Inc. (NASDAQ:QNCX) COO Brendan Hannah Buys 30,845 Shares
Ticker Report Quince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) COO Brendan Hannah purchased 30,845 shares of the stock in a transaction that occurred on Wednesday, August 21st. The stock was purchased at...\n more…
Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex
SeekingAlpha Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex...\n more…
Quince Therapeutics (NASDAQ:QNCX) Trading 1.5% Higher
Ticker Report Quince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) shares rose 1.5% during mid-day trading on Friday . The company traded as high as $0.58 and last traded at $0.55. Approximately 253,213...\n more…